Physician profile
Clifton Smith
NPI 1114991296
$3,872.88
in general payments reported to CMS, 2019-2025
27 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,660 · 2020: $1,333 · 2021: $861 · 2022: $19.59.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $848.44 | 2019-2021 | |
| Galderma Laboratories, L.P. | $395.74 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $386.19 | 2019-2021 | |
| Genentech USA, INC. | $352.00 | 2019-2021 | |
| Ucb, INC. | $264.27 | 2019-2021 | |
| Amgen INC. | $218.93 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $215.80 | 2019-2022 | |
| Pfizer INC. | $160.10 | 2019-2021 | |
| Janssen Biotech, INC. | $132.77 | 2019-2021 | |
| Genzyme Corporation | $126.33 | 2019-2021 | |
| Epi Health, LLC | $96.44 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $95.89 | 2019-2021 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $89.26 | 2019-2021 | |
| Mayne Pharma Commercial LLC | $86.69 | 2019-2020 | |
| Leo Pharma INC. | $85.40 | 2019-2021 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermira, INC. | $66.20 | 2019-2021 | |
| Biofrontera INC. | $63.73 | 2019-2021 | |
| Almirall LLC | $41.97 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $23.14 | 2019 | |
| Lilly USA, LLC | $20.50 | 2021 | |
| Allergan, INC. | $18.84 | 2020 | |
| Biocompatibles, INC. | $17.10 | 2019 | |
| Mallinckrodt Enterprises LLC | $15.23 | 2019 | |
| Dusa Pharmaceuticals, INC. | $14.71 | 2019 | |
| Glenmark Therapeutics INC. | $13.00 | 2019 | |
| Encore Dermatology INC. | $12.19 | 2019 | |
| Melinta Therapeutics, LLC | $12.02 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clifton Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.